PSMA-PET/CT引导的前列腺癌放疗强化:PSMAgRT二期随机试验5年分析
这项二期随机试验纳入262例计划接受标准放疗的前列腺癌患者,随机分入标准治疗或PSMA引导放疗组。5年无失败生存率在两组间无显著差异(66% vs 62%,HR=0.80,p1=0.14),但PSMA引导放疗在高危和根治性前列腺切除术后亚组的无生化进展生存期获益。
要点
- 主要终点5年无失败生存率未达预设阈值,总体人群无显著获益。
- PSMA引导放疗使总体无生化进展生存期从65%提高至72%(sHR 0.70,p1=0.048)。
- 高危和根治性切除术后亚组的无生化进展生存期获益更明显。
核心结论
- 总体人群主要终点无失败生存率未达预设统计学阈值,但治疗效应估计在高危和根治性前列腺切除术后亚组中倾向于PSMA引导放疗。
研究设计与样本
- 二期、两中心、开放标签随机对照试验,2018至2021年随机262例计划接受标准放疗的前列腺癌患者,253例接受治疗并分析。
- 随机1:1分配至标准治疗或PSMA引导放疗,按挽救性根治性前列腺切除术后、高危、寡转移和放疗后挽救四个分层。
主要发现
- 中位随访66个月(范围9-91),5年主要终点无失败生存率PSMA引导放疗组66% vs 对照组62%(HR=0.80;单侧90%CI上限1.04;p1=0.14)。
- 总体无生化进展生存率PSMA引导放疗组72% vs 对照组65%(sHR 0.70;单侧90%CI上限0.92;p1=0.048)。
- 高危疾病患者无生化进展生存率81% vs 66%(sHR 0.54;p1=0.07),根治性前列腺切除术后亚组80% vs 68%(sHR 0.54;p1=0.037)。
- 探索性事后分析合并高危和根治性前列腺切除术后患者,无生化进展生存率倾向于PSMA引导放疗(sHR 0.54,95%CI=0.32-0.91;双侧p=0.02)。
- 仅1例≥3级事件可能与剂量递增相关。
关键数值与推荐
- 主要终点无失败生存率从放疗完成起计算,包括前列腺特异性抗原/影像学进展、下一线治疗或死亡。
- 次要终点无生化进展生存率定义:根治性前列腺切除术后PSA升高≥0.2 ng/ml,其他分层PSA较最低点升高≥2 ng/ml。
- 预设分析采用单侧阈值p1<0.10,事后分析采用双侧p<0.05阈值和95%置信区间。
临床怎么用
- PSMA引导放疗强化在高危和根治性前列腺切除术后患者中可能改善生化控制,支持在正在进行的PATRON三期试验中进一步评估这些目标人群。
局限性
- 二期设计且人群异质性大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate-specific membrane antigen positron emission tomography (PSMA-PET) improves lesion detection, leading to treatment intensification via PSMA-guided radiotherapy (PSMAgRT), but its impact on patient outcomes remains undefined. OBJECTIVE: We evaluated whether PSMAgRT improves failure-free survival (FFS). DESIGN, SETTING, AND PARTICIPANTS: This phase 2, two-center, open-label randomized trial enrolled patients planned for standard-of-care (SOC) radiotherapy (RT). INTERVENTION: Patients were randomized 1:1 to SOC or PSMAgRT to all detected sites across four strata: salvage post-radical prostatectomy (RP), high-risk, oligometastatic, and salvage post-RT. Between 2018 and 2021, 262 patients were randomized (253 treated/analyzed). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary FFS end point (measured from RT completion) comprised prostate-specific antigen (PSA)/radiological progression, next-line therapy, or death. Secondary end points included freedom from biochemical progression (FFBP; PSA rise ≥0.2 ng/ml post-RP or ≥2 ng/ml above nadir in other strata). Prespecified analyses used a one-sided threshold of p1 < 0.10, whereas post hoc analyses used two-sided p < 0.05 thresholds and 95% confidence intervals (CIs). RESULTS AND LIMITATIONS: Among 253 patients, median follow-up was 66 mo (range 9-91). The 5-yr primary FFS was 66% with PSMAgRT versus 62% in controls (hazard ratio [HR] = 0.80; one-sided 90% CI, upper bound 1.04; p1 = 0.14). FFBP favored PSMAgRT: 72% versus 65% overall (subdistribution HR [sHR] 0.70, one-sided 90% CI upper bound 0.92; p1 = 0.048), 81% versus 66% in patients with high-risk disease (sHR 0.54; p1 = 0.07), and 80% versus 68% in patients in post-RP stratum (sHR 0.54; p1 = 0.037). In an exploratory, post hoc analysis combining patients with high-risk disease and those in the post-RP stratum, FFBP favored PSMAgRT (sHR 0.54, 95% CI = 0.32-0.91; two-sided p = 0.02). Only one grade ≥3 event was possibly related to dose escalation. Limitations include a phase 2 design with a heterogeneous population. CONCLUSIONS: Although the primary FFS end point was not met in the overall population, treatment-effect estimates favored PSMAgRT in the high-risk and post-RP strata. These findings provide a meaningful rationale for the target populations currently being evaluated in the definitive phase 3 PATRON trial. TRIAL REGISTRATION: ClinicalTrials.gov NCT03525288.
引用
- Belliveau C, Saad F, Duplan D, et al. PSMA-PET/CT-guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): 5-yr Analysis of a Phase 2 Randomized Controlled Trial. Eur Urol. 2026. PMID: 42829266. doi:10.1016/j.eururo.2026.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。